Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications

J. B. Vermorken, W. J F Van Der Vijgh, I. Klein, H. E. Gall, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time at equal doses (100 mg/m2) but with different infusion times. In rapid, 3-hr and 24-hr infusions, peak levels of free platinum were 8.62, 1.96 and 0.27 μg Pt/ml respectively; half-lives of disposition calculated 0-30 min after the end of each infusion were 17.4, 22.7 and 26.2 min respectively. Free platinum availability, measured as the area under the curves of the free platinum concentration, was the same for the three modes of administration (290, 321 and 325 μg Pt/min/ml-1 respectively). This observation supports the clinical impression that antitumour activity of cisplatin is not dependent on the method of administration.

Original languageEnglish (US)
Pages (from-to)1069-1074
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number11
DOIs
StatePublished - 1982
Externally publishedYes

Fingerprint

Platinum
Cisplatin
Pharmacokinetics
Therapeutics
Area Under Curve
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. / Vermorken, J. B.; Van Der Vijgh, W. J F; Klein, I.; Gall, H. E.; Pinedo, H. M.

In: European Journal of Cancer and Clinical Oncology, Vol. 18, No. 11, 1982, p. 1069-1074.

Research output: Contribution to journalArticle

@article{a6fd9c4330934e29a9d273a06a1d29ab,
title = "Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications",
abstract = "The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time at equal doses (100 mg/m2) but with different infusion times. In rapid, 3-hr and 24-hr infusions, peak levels of free platinum were 8.62, 1.96 and 0.27 μg Pt/ml respectively; half-lives of disposition calculated 0-30 min after the end of each infusion were 17.4, 22.7 and 26.2 min respectively. Free platinum availability, measured as the area under the curves of the free platinum concentration, was the same for the three modes of administration (290, 321 and 325 μg Pt/min/ml-1 respectively). This observation supports the clinical impression that antitumour activity of cisplatin is not dependent on the method of administration.",
author = "Vermorken, {J. B.} and {Van Der Vijgh}, {W. J F} and I. Klein and Gall, {H. E.} and Pinedo, {H. M.}",
year = "1982",
doi = "10.1016/0277-5379(82)90085-2",
language = "English (US)",
volume = "18",
pages = "1069--1074",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications

AU - Vermorken, J. B.

AU - Van Der Vijgh, W. J F

AU - Klein, I.

AU - Gall, H. E.

AU - Pinedo, H. M.

PY - 1982

Y1 - 1982

N2 - The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time at equal doses (100 mg/m2) but with different infusion times. In rapid, 3-hr and 24-hr infusions, peak levels of free platinum were 8.62, 1.96 and 0.27 μg Pt/ml respectively; half-lives of disposition calculated 0-30 min after the end of each infusion were 17.4, 22.7 and 26.2 min respectively. Free platinum availability, measured as the area under the curves of the free platinum concentration, was the same for the three modes of administration (290, 321 and 325 μg Pt/min/ml-1 respectively). This observation supports the clinical impression that antitumour activity of cisplatin is not dependent on the method of administration.

AB - The pharmacokinetics of free platinum species derived from cis-diamminedichloroplatinum (II) (cisplatin) was studied in three patients who received the drug as a single agent for the first time at equal doses (100 mg/m2) but with different infusion times. In rapid, 3-hr and 24-hr infusions, peak levels of free platinum were 8.62, 1.96 and 0.27 μg Pt/ml respectively; half-lives of disposition calculated 0-30 min after the end of each infusion were 17.4, 22.7 and 26.2 min respectively. Free platinum availability, measured as the area under the curves of the free platinum concentration, was the same for the three modes of administration (290, 321 and 325 μg Pt/min/ml-1 respectively). This observation supports the clinical impression that antitumour activity of cisplatin is not dependent on the method of administration.

UR - http://www.scopus.com/inward/record.url?scp=0020426358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020426358&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(82)90085-2

DO - 10.1016/0277-5379(82)90085-2

M3 - Article

C2 - 6891650

AN - SCOPUS:0020426358

VL - 18

SP - 1069

EP - 1074

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 11

ER -